Biltmore Family Office’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $417K | Sell |
17,312
-41
| -0.2% | -$1.07K | 0.05% | 173 |
|
|
2026
Q1 | $487K | Sell |
17,353
-480
| -3% | -$12.8K | 0.07% | 161 |
|
|
2025
Q4 | $444K | Sell |
17,833
-429
| -2% | -$10.8K | 0.06% | 159 |
|
|
2025
Q3 | $465K | Sell |
18,262
-462
| -2% | -$11.4K | 0.07% | 144 |
|
|
2025
Q2 | $454K | Sell |
18,724
-160
| -0.8% | -$3.73K | 0.08% | 133 |
|
|
2025
Q1 | $479K | Buy |
18,884
+353
| +2% | +$9.24K | 0.08% | 130 |
|
|
2024
Q4 | $492K | Sell |
18,531
-114
| -0.6% | -$3.09K | 0.08% | 123 |
|
|
2024
Q3 | $540K | Buy |
18,645
+1,045
| +6% | +$30.5K | 0.09% | 123 |
|
|
2024
Q2 | $492K | Hold |
17,600
| – | – | 0.09% | 114 |
|
|
2024
Q1 | $488K | Buy |
17,600
+153
| +0.9% | +$4.25K | 0.1% | 113 |
|
|
2023
Q4 | $502K | Sell |
17,447
-2,210
| -11% | -$66.8K | 0.1% | 112 |
|
|
2023
Q3 | $652K | Sell |
19,657
-267
| -1% | -$9.44K | 0.15% | 94 |
|
|
2023
Q2 | $731K | Sell |
19,924
-1,607
| -7% | -$62.5K | 0.15% | 87 |
|
|
2023
Q1 | $878K | Buy |
21,531
+242
| +1% | +$10.5K | 0.19% | 80 |
|
|
2022
Q4 | $1.09M | Buy |
21,289
+265
| +1% | +$12.7K | 0.22% | 66 |
|
|
2022
Q3 | $920K | Buy |
21,024
+71
| +0.3% | +$3.45K | 0.21% | 67 |
|
|
2022
Q2 | $1.1M | Sell |
20,953
-720
| -3% | -$36.7K | 0.27% | 62 |
|
|
2022
Q1 | $1.12M | Sell |
21,673
-750
| -3% | -$38.9K | 0.24% | 66 |
|
|
2021
Q4 | $1.32M | Buy |
22,423
+1,223
| +6% | +$60.6K | 0.25% | 65 |
|
|
2021
Q3 | $912K | Sell |
21,200
-1,800
| -8% | -$79.7K | 0.22% | 72 |
|
|
2021
Q2 | $901K | Sell |
23,000
-595
| -3% | -$23.1K | 0.26% | 68 |
|
|
2021
Q1 | $855K | Sell |
23,595
-1,904
| -7% | -$67.6K | 0.27% | 57 |
|
|
2020
Q4 | $939K | Buy |
25,499
+2,499
| +11% | +$91.7K | 0.28% | 57 |
|
|
2020
Q3 | $801K | Sell |
23,000
-141
| -0.6% | -$4.94K | 0.45% | 55 |
|
|
2020
Q2 | $718K | Sell |
23,141
-7,676
| -25% | -$261K | 0.43% | 62 |
|
|
2020
Q1 | $954K | Sell |
30,817
-10,064
| -25% | -$343K | 0.63% | 42 |
|
|
2019
Q4 | $1.52M | Sell |
40,881
-8,229
| -17% | -$293K | 0.61% | 42 |
|
|
2019
Q3 | $1.67M | Buy |
49,110
+19,405
| +65% | +$706K | 0.72% | 44 |
|
|
2019
Q2 | $1.22M | Sell |
29,705
-2,855
| -9% | -$113K | 0.66% | 44 |
|
|
2019
Q1 | $1.31M | Sell |
32,560
-947
| -3% | -$37.9K | 0.67% | 47 |
|
|
2018
Q4 | $1.39M | Buy |
33,507
+666
| +2% | +$27.6K | 0.78% | 42 |
|
|
2018
Q3 | $1.37M | Sell |
32,841
-2,320
| -7% | -$89.3K | 0.65% | 47 |
|
|
2018
Q2 | $1.21M | Sell |
35,161
-53,354
| -60% | -$1.82M | 0.6% | 53 |
|
|
2018
Q1 | $2.98M | Sell |
88,515
-2,545
| -3% | -$87.5K | 1.32% | 23 |
|
|
2017
Q4 | $3.13M | Buy |
+91,060
| New | +$3.1M | 1.41% | 22 |
|
Other funds holding PFE
Biltmore Family Office's PFE Position: Q2 2026 in Review
Biltmore Family Office reduced its Pfizer (PFE) stake by 0.24% in Q2 2026, selling an estimated $1.07K and leaving 17,312 shares worth $417K. The position accounts for 0.05% of the portfolio, ranked #173.
Biltmore Family Office first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $3.13M in Q4 2017. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Biltmore Family Office held 17,312 shares of Pfizer worth $417K as of Q2 2026.
- Biltmore Family Office sold 41 Pfizer shares in Q2 2026, an estimated $1.07K.
- Pfizer made up 0.05% of Biltmore Family Office's portfolio in Q2 2026, its #173 holding.
- Biltmore Family Office first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Biltmore Family Office's Pfizer position peaked at $3.13M in Q4 2017.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Biltmore Family Office's 13F filing for Q2 2026, filed 12 Aug 2026.